The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial.

Authors

null

Astrid E. Slagter

Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, Netherlands

Astrid E. Slagter , Marieke A. Vollebergh , Irene A Caspers , Johanna W. van Sandick , Karolina Sikorska , Pehr A. Lind , Marianne Nordsmark , Hein Putter , Jeffrey P.B.M. Braak , Elma Meershoek – Klein Kranenbarg , Cornelis J.H. Van De Velde , Edwin PM Jansen , Annemieke Cats , Hanneke W.M. Van Laarhoven , Nicole C.T. van Grieken , Marcel Verheij

Organizations

Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, Netherlands, Karolinska Institute/Stockholm Soder Hospital, Stockholm, Sweden, Aarhus University Hospital, Aarhus, Denmark, Leiden University Medical Center, Department of Medical Statistics, Leiden, Netherlands, Leids Universitair Medisch Centrum, Leiden, Netherlands, Leiden University Medical Center, Department of Surgery, Leiden, Netherlands, Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands

Research Funding

Other
Dutch Cancer Society, Dutch Colorectal Cancer Groupp, Hoffman La Roche

Background: Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are well-known tumor markers. Most studies on CEA and CA 19-9 in pts with GC were performed in Asia, and/or in the metastatic setting. The aim of this study was to investigate the prognostic value of blood derived laboratory parameters in a cohort of European pts with resectable non-metastatic GC. Methods: In the CRITICS trial, 788 pts with resectable GC underwent perioperative therapy (preoperative chemotherapy plus either postoperative chemotherapy or postoperative chemoradiotherapy). Blood levels of CEA, CA 19-9, alkaline phosphatase (AP), creatinine, neutrophils, hemoglobin (Hb) and lactate dehydrogenase (LDH) were determined prior to treatment. Data for these variables were available for at least 89% of the pts. Factors significant on univariable cox regression analysis were further explored in multivariable analysis. Probabilities to undergo potentially curative surgery was investigated for factors significant on multivariable analysis. The relationship between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 pts with available ctDNA data. Results: CEA and CA 19-9 were identified as independent prognostic factors for survival (Table). Probabilities to undergo potentially curative surgery were 86%, 77% and 60% for pts with no elevated tumor makers versus those with elevated CEA or elevated CA 19-9 versus those with both tumor markers elevated, respectively (p<0.001). No relationship was found between elevated tumor marker(s) and the presence of ctDNA neither pretreatment nor preoperatively. Conclusions: Pretreatment blood levels of CEA and CA 19-9 were identified as prognostic factors for overall survival in a large cohort of European GC pts with potentially curable disease. These factors may guide treatment choices at an early phase and should be included in future trials to determine their role in clinical decision making.

Uni-/multivariable analysis on overall survival.


Factor1
Hazard ratio
95% CI
p value
Univariable analysis2
CEA
1.45
1.15-1.84
0.002
CA 19-9
1.75
1.42-2.16
<0.001
CEA + CA 19-9

Both ≤ULN

CEA or CA 19-9 >ULN

Both >ULN


*

1.46

2.45




1.17-1.81

1.77-1.39




0.001

<0.001
AP
1.14
0.78-1.66
0.488
Creatinine
0.60
0.39-1.07
0.082
Neutrophils
0.89
0.64-1.22
0.450
Hb
1.09
0.91-1.30
0.372
LDH
1.08
0.81-1.43
0.594
Multivariable analysis3
CEA + CA 19-9

Both ≤ULN

CEA or CA 19-9 >ULN

Both >ULN


*

1.57

2.65


1.24-2.00

1.86-3.76


<0.001

<0.001

1All factors were tested categorically (cut-off according to local reference). The lower category was used as reference. 2Additional included factors of which the data is not shown are age, sex, performance status (PS), Lauren classification, tumor localization and body mass index (BMI); 3Additional included factors of which the data is not shown are Lauren classification, PS and BMI. *reference.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4024)

DOI

10.1200/JCO.2021.39.15_suppl.4024

Abstract #

4024

Poster Bd #

Online Only

Abstract Disclosures